A preclinical study published in the journal Nature revealed a potential advance in the fight against HIV. According to the report, a single injection of gene therapy administered at birth could offer years of protection against HIV by exploiting a critical window in the early moments of life. Newborn macaques that received the treatment were protected from infection for at least three years, demonstrating the potential of early intervention.
HIV transmission to children is a major concern, with over 100,000 pediatric cases occurring each year, largely through mother-to-child transmission during breastfeeding. Ninety percent of these cases are found in sub-Saharan Africa. The study's findings suggest that targeting this early stage could transform HIV prevention strategies, providing an effective and long-lasting solution where it is most needed.
The gene therapy used a common shuttle, adeno-associated virus (AAV), to deliver genetic instructions for cells to produce HIV-fighting antibodies. The research showed that these engineered cells acted as "micro-factories," continually producing broadly neutralizing antibodies (bNAbs) capable of neutralizing multiple HIV strains. This method could overcome the challenges posed by traditional antibody administration, which often requires costly and repeated dosing in resource-limited settings.
The therapy's success lay in its timing. The injections were implemented during the first month of life, maximizing the body's tolerance to the treatment and ensuring prolonged protection. “This new hypothesis could help protect newborns in high-risk areas during the most vulnerable period of their lives,” said Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center.
The research also highlighted a novel observation: exposing fetuses to antibodies before birth appeared to condition infants to better accept the therapy later. This finding could have implications for managing the immune system's tendency to reject outside interventions as the body matures. In contrast, treatments administered to older infants and juveniles were less successful, as these subjects tended to produce antibodies against the gene therapy.
The study, involving 65 rhesus macaques, provided compelling evidence for the efficacy of this approach. “This strategy offers a relatively simple method of preventing HIV-1 transmission during breastfeeding, particularly in regions with limited medical resources,” said lead author Mauricio Martins, Ph.D., from The Wertheim UF Scripps Institute. If successful in human trials, this gene therapy could dramatically reduce mother-to-child HIV transmission rates in high-risk regions, underscoring the importance of prioritizing interventions that don't rely on repeated dosing.
While the results are promising, challenges remain. Researchers acknowledged that they have not yet tested the gene therapy on human children, leaving questions about its effectiveness and applicability unanswered. The next steps involve developing a pediatric proof-of-concept trial with the support of the Gates Foundation, seeking to refine dosages for infants and ensure safety.
“This was a huge result, and now we have all the ingredients to take on HIV,” said Ardeshir. Should the approach prove successful in humans, it represents a potential breakthrough in HIV treatment, offering a feasible and cost-effective solution to protect children from infection in areas where the disease is most prevalent.
Assisted by a news-analysis system.